Short answer
OCULAR THERAPEUTIX, INC (OCUL) filed an 8-K current report with the SEC on May 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Section 2.02 text contains only disclosure-law disclaimers.
OCULAR THERAPEUTIX, INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Section 2.02 text contains only disclosure-law disclaimers
- No earnings figures, reporting period, operating results, or financial guidance provided
- Investors must review the referenced exhibit for substantive results information
Item EX-99.1 · Exhibit EX-99.1
- Q1 2026 net revenue $10.8M, up 0.8% from $10.7M; commercial revenue remained stable
- Net loss widened to $88.6M, or $0.40 per share, from $64.1M, reflecting heavier development spending
- Cash balance $666.7M supports planned operations into 2028, excluding full potential AXPAXLI commercialization costs
- SOL-1 superiority results strengthen AXPAXLI’s regulatory case: 65.9% maintained vision at Week 52 versus 44.2% for aflibercept
- NDA submission planned using SOL-1 Week 52 data, subject to FDA discussions; SOL-R topline data targeted for 1Q 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other OCULAR THERAPEUTIX, INC 8-K filings
Get the next OCUL 8-K as it lands
Follow OCUL for push alerts, or ask the research agent what this filing means.